Skip to main content
NCBI home page
Neurotherapeutics logoLink to Neurotherapeutics
. 2010 Apr;7(2):164–175. doi: 10.1016/j.nurt.2010.02.004

CGRP receptor antagonism and migraine

Lars Edvinsson 1,✉, Tony W Ho 2
PMCID: PMC5084097  PMID: 20430315

Summary

Calcitonin gene-related peptide (CGRP) is expressed throughout the central and peripheral nervous systems, consistent with control of vasodilatation, nociception, motor function, secretion, and olfaction. αCGRP is prominently localized in primary spinal afferent C and AA fibers of sensory ganglia, and βCGRP is the main isoform in the enteric nervous system. In the CNS there is a wide distribution of CGRP-containing neurons, with the highest levels occurring in striatum, amygdala, colliculi, and cerebellum. The peripheral projections are involved in neurogenic vasodilatation and inflammation, and central release induces hyperalgesia. CGRP is released from trigeminal nerves in migraine. Trigeminal nerve activation results in antidromic release of CGRP to cause non-endothelium-mediated vasodilatation. At the central synapses in the trigeminal nucleus caudalis, CGRP acts postjunctionally on second-order neurons to transmit pain signals centrally via the brainstem and midbrain to the thalamus and higher cortical pain regions. Recently developed CGRP receptor antagonists are effective at aborting acute migraine attacks. They may act both centrally and peripherally to attenuate signaling within the trigeminovascular pathway.

Key Words: Migraine, CGRP, trigeminovascular, CGRP receptor antagonists

References

  • 1.Ray B, Wolff H. Experimental studies on headache: pain sensitive structures of the head and their significance in headache. Arc Surg. 1940;4:813–856. [Google Scholar]
  • 2.Goadsby PJ, Edvinsson L, Ekman R. Release of vasoactive peptides in the extracerebral circulation of humans and the cat during activation of the trigeminovascular system. Ann Neurol. 1988;23:193–196. doi: 10.1002/ana.410230214. [DOI] [PubMed] [Google Scholar]
  • 3.Tajti J, Uddman R, Möller S, Sundler F, Edvinsson L. Messenger molecules and receptor mRNA in the human trigeminal ganglion. J Auton Nerv Syst. 1999;76:176–183. doi: 10.1016/S0165-1838(99)00024-7. [DOI] [PubMed] [Google Scholar]
  • 4.Goadsby PJ, Edvinsson L. The trigeminovascular system and migraine: studies characterizing cerebrovascular and neuropeptide changes seen in humans and cats. Ann Neurol. 1993;33:48–56. doi: 10.1002/ana.410330109. [DOI] [PubMed] [Google Scholar]
  • 5.Goadsby PJ. Inhibition of calcitonin gene-related peptide by h-CGRP8–37 antagonizes the cerebral dilator response from nasociliary nerve stimulation in the cat. Neurosci Lett. 1993;151:13–16. doi: 10.1016/0304-3940(93)90033-H. [DOI] [PubMed] [Google Scholar]
  • 6.Edvinsson L, Mulder H, Goadsby PJ, Uddman R. Calcitonin gene-related peptide and nitric oxide in the trigeminal ganglion: cerebral vasodilatation from trigeminal nerve stimulation involves mainly calcitonin gene-related peptide. J Auton Nerv Syst. 1998;70:15–22. doi: 10.1016/S0165-1838(98)00033-2. [DOI] [PubMed] [Google Scholar]
  • 7.Amara SG, Jonas V, Rosenfeld MG, Ong ES, Evans RM. Alternative RNA processing in calcitonin gene expression generates mRNAs encoding different polypeptide products. Nature. 1982;298:240–244. doi: 10.1038/298240a0. [DOI] [PubMed] [Google Scholar]
  • 8.Mulderry PK, Ghatei MA, Spokes RA, et al. Differential expression of α-CGRP and β-CGRP by primary sensory neurons and enteric autonomic neurons of the rat. Neuroscience. 1988;25:195–205. doi: 10.1016/0306-4522(88)90018-8. [DOI] [PubMed] [Google Scholar]
  • 9.Brain SD, Cambridge H. Calcitonin gene-related peptide: vasoactive effects and potential therapeutic role. Gen Pharmacol. 1996;27:607–611. doi: 10.1016/0306-3623(95)00125-5. [DOI] [PubMed] [Google Scholar]
  • 10.Sexton PM. Central nervous system binding sites for calcitonin and calcitonin gene-related peptide. Mol Neurobiol. 1991;5:251–273. doi: 10.1007/BF02935550. [DOI] [PubMed] [Google Scholar]
  • 11.van Rossum D, Hanisch UK, Quirion R. Neuroanatomical localization, pharmacological characterization and functions of CGRP, related peptides and their receptors. Neurosci Biobehav Rev. 1997;21:649–678. doi: 10.1016/S0149-7634(96)00023-1. [DOI] [PubMed] [Google Scholar]
  • 12.Gendek-Kubiak H, Kmieć BL. Immunolocalization of CGRP, NPY and PGP 9.5 in guinea pig skin. Folia Morphol (Warsz) 2004;63:115–117. [PubMed] [Google Scholar]
  • 13.Swartling C, Naver H, Pihl-Lundin I, Hagforsen E, Vahlquist A. Sweat gland morphology and periglandular innervation in essential palmar hyperhidrosis before and after treatment with intradermal botulinum toxin. J Am Acad Dermatol. 2004;51:739–745. doi: 10.1016/j.jaad.2004.07.030. [DOI] [PubMed] [Google Scholar]
  • 14.Fernandez HL, Ross GS, Nadelhaft I. Neurogenic calcitonin gene-related peptide: a neurotrophic factor in the maintenance of acetylcholinesterase molecular forms in adult skeletal muscles. Brain Res. 1999;844:83–97. doi: 10.1016/S0006-8993(99)01891-0. [DOI] [PubMed] [Google Scholar]
  • 15.Hayakawa T, Kuwahara S, Maeda S, Tanaka K, Seki M. Distribution of vagal CGRP-immunoreactive fibers in the lower esophagus and the cardia of the stomach of the rat. J Chem Neuroanat. 2009;38:124–129. doi: 10.1016/j.jchemneu.2009.04.001. [DOI] [PubMed] [Google Scholar]
  • 16.Hökfelt T, Arvidsson U, Ceccatelli S, et al. Calcitonin generelated peptide in the brain, spinal cord, and some peripheral systems. Ann N Y Acad Sci. 1992;657:119–134. doi: 10.1111/j.1749-6632.1992.tb22762.x. [DOI] [PubMed] [Google Scholar]
  • 17.Liu Y, Zhang M, Broman J, Edvinsson L. Central projections of sensory innervation of the rat superficial temporal artery. Brain Res. 2003;966:126–133. doi: 10.1016/S0006-8993(02)04222-1. [DOI] [PubMed] [Google Scholar]
  • 18.Arbab MA, Delgado T, Wiklund L, Svendgaard NA. Brain stem terminations of the trigeminal and upper spinal ganglia innervation of the cerebrovascular system: WGA-HRP transganglionic study. J Cereb Blood Flow Metab. 1988;8:54–63. doi: 10.1038/jcbfm.1988.8. [DOI] [PubMed] [Google Scholar]
  • 19.Poyner DR. Calcitonin gene-related peptide: multiple actions, multiple receptors. Pharmacol Ther. 1992;56:23–51. doi: 10.1016/0163-7258(92)90036-Y. [DOI] [PubMed] [Google Scholar]
  • 20.Gulbenkian S, Uddman R, Edvinsson L. Neuronal messengers in the human cerebral circulation. Peptides. 2001;22:995–1007. doi: 10.1016/S0196-9781(01)00408-9. [DOI] [PubMed] [Google Scholar]
  • 21.Gregg KV, Bishop GA, King JS. Fine structural analysis of calcitonin gene-related peptide in the mouse inferior olivary complex. J Neurocytol. 1999;28:431–438. doi: 10.1023/A:1007032119792. [DOI] [PubMed] [Google Scholar]
  • 22.Quayle JM, Bonev AD, Brayden JE, Nelson MT. Calcitonin gene-related peptide activated ATP-sensitive K+ currents in rabbit arterial smooth muscle via protein kinase A. J Physiol. 1994;475:9–13. doi: 10.1113/jphysiol.1994.sp020045. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Edvinsson L. Functional role of perivascular peptides in the control of cerebral circulation. Trends Neurosci. 1985;8:126–131. doi: 10.1016/0166-2236(85)90050-5. [DOI] [Google Scholar]
  • 24.Rossi SG, Dickerson IM, Rotundo RL. Localization of the calcitonin gene-related peptide receptor complex at the vertebrate neuromuscular junction and its role in regulating acetylcholinesterase expression. J Biol Chem. 2003;278:24994–25000. doi: 10.1074/jbc.M211379200. [DOI] [PubMed] [Google Scholar]
  • 25.Todd KJ, Robitaille R. Neuron-glia interactions at the neuromuscular synapse. Novartis Found Symp. 2006;276:222–229. doi: 10.1002/9780470032244.ch17. [DOI] [PubMed] [Google Scholar]
  • 26.Al-Kazwini SJ, Craig RK, Marshall I. Postjunctional inhibition of contractor responses in the mouse vas deferens by rat and human calcitonin gene-related peptides (CGRP) Br J Pharmacol. 1986;88:173–180. doi: 10.1111/j.1476-5381.1986.tb09484.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Tarabal O, Calderó J, Ribera J, et al. Regulation of motoneuronal calcitonin gene-related peptide (CGRP) during axonal growth and neuromuscular synaptic plasticity induced by botulinum toxin in rats. Eur J Neurosci. 1996;8:829–836. doi: 10.1111/j.1460-9568.1996.tb01269.x. [DOI] [PubMed] [Google Scholar]
  • 28.Tsukiji J, Sango K, Udaka N, et al. Long-term induction of β-CGRP mRNA in rat lungs by allergic inflammation. Life Sci. 2004;76:163–177. doi: 10.1016/j.lfs.2004.05.038. [DOI] [PubMed] [Google Scholar]
  • 29.Ren YH, Qin XQ, Guan CX, Luo ZQ, Zhang CQ, Sun XH. Temporal and spatial distribution of VIP, CGRP and their receptors in the development of airway hyperresponsiveness in the lungs. Sheng Li Xue Bao. 2004;56:137–146. [PubMed] [Google Scholar]
  • 30.Kang JM, Kim N, Kim B, et al. Gastroprotective action of cochinchina momordica seed extract is mediated by activation of CGRP and inhibition of cPLA2/5-LOX pathway. Dig Dis Sci. 2009;54:2549–2560. doi: 10.1007/s10620-008-0671-6. [DOI] [PubMed] [Google Scholar]
  • 31.Rasmussen TN, Schmidt P, Poulsen SS, Holst JJ. Effect of calcitonin gene-related peptide (CGRP) on motility and on the release of substance P, neurokinin A, somatostatin and gastrin in the isolated perfused porcine antrum. Neurogastroenterol Motil. 2001;13:353–359. doi: 10.1046/j.1365-2982.2001.00274.x. [DOI] [PubMed] [Google Scholar]
  • 32.Zhang Z, Winborn CS, Marquez de Prado B, Russo AF. Sensitization of calcitonin gene-related peptide receptors by receptor activity-modifying protein-1 in the trigeminal ganglion. J Neurosci. 2007;27:2693–2703. doi: 10.1523/JNEUROSCI.4542-06.2007. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Thalakoti S, Patil VV, Damodaram S, et al. Neuron-glia signaling in trigeminal ganglion: implications for migraine pathology. Headache. 2007;47:1008–1023. doi: 10.1111/j.1526-4610.2007.00854.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.Li J, Vause CV, Durham PL. Calcitonin gene-related peptide stimulation of nitric oxide synthesis and release from trigeminal ganglion glial cells. Brain Res. 2008;1196:22–32. doi: 10.1016/j.brainres.2007.12.028. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.Li XF, Kinsey-Jones JS, Bowe JE, et al. A role for the medial preoptic area in CGRP-induced suppression of pulsatile LH secretion in the female rat. Stress. 2009;12:259–267. doi: 10.1080/10253890802379922. [DOI] [PubMed] [Google Scholar]
  • 36.Uddman R, Edvinsson L, Ekman R, Kingman T, McCulloch J. Innervation of the feline cerebral vasculature by nerve fibers containing calcitonin gene-related peptide: trigeminal origin and co-existence with substance P. Neurosci Lett. 1985;62:131–136. doi: 10.1016/0304-3940(85)90296-4. [DOI] [PubMed] [Google Scholar]
  • 37.McCulloch J, Uddman R, Kingman TA, Edvinsson L. Calcitonin gene-related peptide: functional role in cerebrovascular regulation. Proc Natl Acad Sci U S A. 1986;83:5731–5735. doi: 10.1073/pnas.83.15.5731. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38.Edvinsson L. Blockade of CGRP receptors in the intracranial vasculature: a new target in the treatment of headache. Cephalalgia. 2004;24:611–622. doi: 10.1111/j.1468-2982.2003.00719.x. [DOI] [PubMed] [Google Scholar]
  • 39.Jansen-Olesen I, Mortensen A, Edvinsson L. Calcitonin generelated peptide is released from capsaicin-sensitive nerve fibres and induces vasodilatation of human cerebral arteries concomitant with activation of adenylyl cyclase. Cephalalgia. 1996;16:310–316. doi: 10.1046/j.1468-2982.1996.1605310.x. [DOI] [PubMed] [Google Scholar]
  • 40.Edvinsson L, Jansen I, Kingman TA, McCulloch J. Cerebrovascular responses to capsaicin in vitro and in situ. Br J Pharmacol. 1990;100:312–318. doi: 10.1111/j.1476-5381.1990.tb15801.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 41.Grant AD, Pinter E, Salmon AM, Brain SD. An examination of neurogenic mechanisms involved in mustard oil-induced inflammation in the mouse. Eur J Pharmacol. 2005;507:273–280. doi: 10.1016/j.ejphar.2004.11.026. [DOI] [PubMed] [Google Scholar]
  • 42.Petersen KA, Birk S, Doods H, Edvinsson L, Olesen J. Inhibitory effect of BIBN4096BS on cephalic vasodilatation induced by CGRP or transcranial electrical stimulation in the rat. Br J Pharmacol. 2004;143:697–704. doi: 10.1038/sj.bjp.0705966. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 43.Goadsby PJ, Edvinsson L. Joint 1994 Wolff Award Presentation. Peripheral and central trigeminovascular activation in cat is blocked by the serotonin (5HT)-1D receptor agonist 311C90. Headache. 1994;34:394–399. doi: 10.1111/j.1526-4610.1994.hed3407394.x. [DOI] [PubMed] [Google Scholar]
  • 44.Mayberg M, Langer RS, Zervas NT, Moskowitz MA. Perivascular meningeal projections from cat trigeminal ganglia: possible pathway for vascular headaches in man. Science. 1981;213:228–230. doi: 10.1126/science.6166046. [DOI] [PubMed] [Google Scholar]
  • 45.Edvinsson L, Hara H, Uddman R. Retrograde tracing of nerve fibers to the rat middle cerebral artery with true blue: colocalization with different peptides. J Cereb Blood Flow Metab. 1989;9:212–218. doi: 10.1038/jcbfm.1989.31. [DOI] [PubMed] [Google Scholar]
  • 46.Uddman R, Hara H, Edvinsson L. Neuronal pathways to the rat middle meningeal artery revealed by retrograde tracing and immunocytochemistry. J Auton Nerv Syst. 1989;26:69–75. doi: 10.1016/0165-1838(89)90109-4. [DOI] [PubMed] [Google Scholar]
  • 47.Liu Y, Broman J, Edvinsson L. Central projections of sensory innervation of the rat superior sagittal sinus. Neuroscience. 2004;129:431–437. doi: 10.1016/j.neuroscience.2004.07.045. [DOI] [PubMed] [Google Scholar]
  • 48.Edvinsson L, Uddman R. Neurobiology in primary headaches. Brain Res Brain Res Rev. 2005;48:438–456. doi: 10.1016/j.brainresrev.2004.09.007. [DOI] [PubMed] [Google Scholar]
  • 49.Tran Dinh YR, Thurel C, Serrie A, Cunin G, Seylaz J. Glycerol injection into the trigeminal ganglion provokes a selective increase in human cerebral blood flow. Pain. 1991;46:13–16. doi: 10.1016/0304-3959(91)90027-U. [DOI] [PubMed] [Google Scholar]
  • 50.Goadsby PJ, Edvinsson L, Ekman R. Cutaneous sensory stimulation leading to facial flushing and release of calcitonin generelated peptide. Cephalalgia. 1992;12:53–56. doi: 10.1046/j.1468-2982.1992.1201053.x. [DOI] [PubMed] [Google Scholar]
  • 51.Goadsby PJ, Edvinsson L, Ekman R. Vasoactive peptide release in the extracerebral circulation of humans during migraine headache. Ann Neurol. 1990;28:183–187. doi: 10.1002/ana.410280213. [DOI] [PubMed] [Google Scholar]
  • 52.Pietrobon D. Migraine: new molecular mechanisms. Neuroscientist. 2005;11:373–386. doi: 10.1177/1073858405275554. [DOI] [PubMed] [Google Scholar]
  • 53.Ophoff RA, Terwindt GM, Vergouwe MN, et al. Familial hemiplegic migraine and episodic ataxia type-2 are caused by mutations in the Ca2+ channel gene CACNL1A4. Cell. 1996;87:543–552. doi: 10.1016/S0092-8674(00)81373-2. [DOI] [PubMed] [Google Scholar]
  • 54.van de Ven RC, Kaja S, Plomp JJ, et al. Genetic models of migraine. Arch Neurol. 2007;64:643–646. doi: 10.1001/archneur.64.5.643. [DOI] [PubMed] [Google Scholar]
  • 55.Woods RP, Iacoboni M, Mazziotta JC. Brief report: bilateral spreading cerebral hypoperfusion during spontaneous migraine headache. N Engl J Med. 1994;331:1689–1692. doi: 10.1056/NEJM199412223312505. [DOI] [PubMed] [Google Scholar]
  • 56.Hadjikhani N, Sanchez Del Rio M, Wu O, et al. Mechanisms of migraine aura revealed by functional MRI in human visual cortex. Proc Natl Acad Sci U S A. 2001;98:4687–4692. doi: 10.1073/pnas.071582498. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 57.Welch KM, Cao Y, Aurora S, Wiggins G, Vikingstad EM. MRI of the occipital cortex, red nucleus, and substantia nigra during visual aura of migraine. Neurology. 1998;51:1465–1469. doi: 10.1212/wnl.51.5.1465. [DOI] [PubMed] [Google Scholar]
  • 58.Cao Y, Aurora SK, Nagesh V, Patel SC, Welch KM. Functional MRI-BOLD of brainstem structures during visually triggered migraine. Neurology. 2002;59:72–78. doi: 10.1212/wnl.59.1.72. [DOI] [PubMed] [Google Scholar]
  • 59.Edvinsson L, Degueurce A, Duverger D, MacKenzie ET, Scatton B. Central serotonergic nerves project to the pial vessels of the brain. Nature. 1983;306:55–57. doi: 10.1038/306055a0. [DOI] [PubMed] [Google Scholar]
  • 60.Olesen J, Thomsen LL, Iversen H. Nitric oxide is a key molecule in migraine and other vascular headaches. Trends Pharmacol Sci. 1994;15:149–153. doi: 10.1016/0165-6147(94)90075-2. [DOI] [PubMed] [Google Scholar]
  • 61.Juhasz G, Zsombok T, Jakab B, Nemeth J, Szolcsanyi J, Bagdy G. Sumatriptan causes parallel decrease in plasma calcitonin gene-related peptide (CGRP) concentration and migraine headache during nitroglycerin induced migraine attack. Cephalalgia. 2005;25:179–183. doi: 10.1111/j.1468-2982.2005.00836.x. [DOI] [PubMed] [Google Scholar]
  • 62.Juhasz G, Zsombok T, Modos EA, et al. NO-induced migraine attack: strong increase in plasma calcitonin gene-related peptide (CGRP) concentration and negative correlation with platelet serotonin release. Pain. 2003;106:461–470. doi: 10.1016/j.pain.2003.09.008. [DOI] [PubMed] [Google Scholar]
  • 63.Kruuse C, Iversen H, Jansen-Olesen I, Edvinsson L, Olesen J. Calcitonin gene-related peptide (CGRP) levels during glyceryl trinitrate (GTN)-induced headache in healthy volunteers. Cephalalgia 2009 Aug 11 [Epub ahead of print]. [DOI] [PubMed]
  • 64.Stepień A, Jagustyn P, Trafny EA, Widerkiewicz K. Suppressing effect of the serotonin 5HT1B/D receptor agonist rizatriptan on calcitonin gene-related peptide (CGRP) concentration in migraine attacks [In Polish] Neurol Neurochir Pol. 2003;37:1013–1023. [PubMed] [Google Scholar]
  • 65.Tvedskov JF, Lipka K, Ashina M, Iversen HK, Schifter S, Olesen J. No increase of calcitonin gene-related peptide in jugular blood during migraine. Ann Neurol. 2005;58:561–568. doi: 10.1002/ana.20605. [DOI] [PubMed] [Google Scholar]
  • 66.Juul R, Edvinsson L, Gisvold SE, Ekman R, Brubakk AO, Fredriksen TA. Calcitonin gene-related peptide-LI in subarachnoid haemorrhage in man: signs of activation of the trigeminocerebrovascular system? Br J Neurosurg. 1990;4:171–179. doi: 10.3109/02688699008992720. [DOI] [PubMed] [Google Scholar]
  • 67.Juul R, Hara H, Gisvold SE, et al. Alterations in perivascular dilatory neuropeptides (CGRP, SP, VIP) in the external jugular vein and in the cerebrospinal fluid following subarachnoid haemorrhage in man. Acta Neurochir (Wien) 1995;132:32–41. doi: 10.1007/BF01404845. [DOI] [PubMed] [Google Scholar]
  • 68.Smith D, Hill RG, Edvinsson L, Longmore J. An immunocytochemical investigation of human trigeminal nucleus caudalis: CGRP, substance P and 5-HT1D-receptor immunoreactivities are expressed by trigeminal sensory fibres. Cephalalgia. 2002;22:424–431. doi: 10.1046/j.1468-2982.2002.00378.x. [DOI] [PubMed] [Google Scholar]
  • 69.Nilsson T, et al. Characterisation of 5-HT receptors in human coronary arteries by molecular and pharmacological techniques. Eur J Pharmacol. 1999;372:49–56. doi: 10.1016/S0014-2999(99)00114-4. [DOI] [PubMed] [Google Scholar]
  • 70.Waugh DJ, Bockman CS, Smith DD, Abel PW. Limitations in using peptide drugs to characterize calcitonin gene-related peptide receptors. J Pharmacol Exp Ther. 1999;289:1419–1426. [PubMed] [Google Scholar]
  • 71.McLatchie LM, Fraser NJ, Main MJ, et al. RAMPs regulate the transport and ligand specificity of the calcitonin-receptor-like receptor. Nature. 1998;393:333–339. doi: 10.1038/30666. [DOI] [PubMed] [Google Scholar]
  • 72.Foord SM, Marshall FH. RAMPs: accessory proteins for seven transmembrane domain receptors. Trends Pharmacol Sci. 1999;20:184–187. doi: 10.1016/S0165-6147(99)01347-4. [DOI] [PubMed] [Google Scholar]
  • 73.Hay DL, Poyner DR, Quirion R, International Union of Pharmacology International Union of Pharmacology. LXIX. Status of the calcitonin gene-related peptide subtype 2 receptor. Pharmacol Rev. 2008;60:143–145. doi: 10.1124/pr.108.00372. [DOI] [PubMed] [Google Scholar]
  • 74.Oliver KR, Wainwright A, Edvinsson L, Pickard JD, Hill RG. Immunohistochemical localization of calcitonin receptor-like receptor and receptor activity-modifying proteins in the human cerebral vasculature. J Cereb Blood Flow Metab. 2002;22:620–629. doi: 10.1097/00004647-200205000-00014. [DOI] [PubMed] [Google Scholar]
  • 75.Lennerz JK, Rühle V, Ceppa EP, et al. Calcitonin receptor-like receptor (CLR), receptor activity-modifying protein 1 (RAMP1), and calcitonin gene-related peptide (CGRP) immunoreactivity in the rat trigeminovascular system: differences between peripheral and central CGRP receptor distribution. J Comp Neurol. 2008;507:1277–1299. doi: 10.1002/cne.21607. [DOI] [PubMed] [Google Scholar]
  • 76.Petersen KA, Nilsson E, Olesen J, Edvinsson L. Presence and function of the calcitonin gene-related peptide receptor on rat pial arteries investigated in vitro and in vivo. Cephalalgia. 2005;25:424–432. doi: 10.1111/j.1468-2982.2005.00869.x. [DOI] [PubMed] [Google Scholar]
  • 77.Edvinsson L, Cantera L, Jansen-Olesen I, Uddman R. Expression of calcitonin gene-related peptide1 receptor mRNA in human trigeminal ganglia and cerebral arteries. Neurosci Lett. 1997;229:209–211. doi: 10.1016/S0304-3940(97)00456-4. [DOI] [PubMed] [Google Scholar]
  • 78.Sams A, Jansen-Olesen I. Expression of calcitonin receptor-like receptor and receptor-activity-modifying proteins in human cranial arteries. Neurosci Lett. 1998;258:41–44. doi: 10.1016/S0304-3940(98)00844-1. [DOI] [PubMed] [Google Scholar]
  • 79.Doods H, Hallermayer G, Wu D, et al. Pharmacological profile of BIBN4096BS, the first selective small molecule CGRP antagonist. Br J Pharmacol. 2000;129:420–423. doi: 10.1038/sj.bjp.0703110. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 80.Edvinsson L, Sams A, Jansen-Olesen I, et al. Characterisation of the effects of a non-peptide CGRP receptor antagonist in SK-N-MC cells and isolated human cerebral arteries. Eur J Pharmacol. 2001;415:39–44. doi: 10.1016/S0014-2999(00)00934-1. [DOI] [PubMed] [Google Scholar]
  • 81.Verheggen R, Bumann K, Kaumann AJ. BIBN4096BS is a potent competitive antagonist of the relaxant effects of α-CGRP on human temporal artery: comparison with CGRP8–37. Br J Pharmacol. 2002;136:120–126. doi: 10.1038/sj.bjp.0704682. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 82.Edvinsson L, Alm R, Shaw D, et al. Effect of the CGRP receptor antagonist BIBN4096BS in human cerebral, coronary and omental arteries and in SK-N-MC cells. Eur J Pharmacol 202;434:49–53. [DOI] [PubMed]
  • 83.Mallee JJ, Salvatore CA, LeBourdelles B, et al. Receptor activity-modifying protein 1 determines the species selectivity of non-peptide CGRP receptor antagonists. J Biol Chem. 2002;277:14294–14298. doi: 10.1074/jbc.M109661200. [DOI] [PubMed] [Google Scholar]
  • 84.Edvinsson L, McCulloch J, Kingman T, Uddman R. On the functional role of the trigemino-cerebrovascular system in the regulation of cerebral circulation. In: Owman C, Hardebo JE, editors. Neural regulation of the cerebral circulation. Amsterdam: Elsevier Science; 1986. pp. 407–418. [Google Scholar]
  • 85.Petersen KA, Birk S, Lassen LH, et al. The CGRP-antagonist, BIBN4096BS does not affect cerebral or systemic haemodynamics in healthy volunteers. Cephalalgia. 2005;25:139–147. doi: 10.1111/j.1468-2982.2004.00830.x. [DOI] [PubMed] [Google Scholar]
  • 86.Petersen KA, Lassen LH, Birk S, Lesko L, Olesen J. BIBN4096BS antagonizes human α-calcitonin gene related peptide-induced headache and extracerebral artery dilatation. Clin Pharmacol Ther. 2005;77:202–213. doi: 10.1016/j.clpt.2004.10.001. [DOI] [PubMed] [Google Scholar]
  • 87.Edvinsson L, Nilsson E, Jansen-Olesen I. Inhibitory effect of BIBN4096BS, CGRP(8–37), a CGRP antibody and an RNA-Spiegelmer on CGRP induced vasodilatation in the perfused and non-perfused rat middle cerebral artery. Br J Pharmacol. 2007;150:633–640. doi: 10.1038/sj.bjp.0707134. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 88.Olesen J, Diener HC, Husstedt IW, BIBN 4096 BS Clinical Roof of Concept Study Group et al. Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine. N Engl J Med. 2004;350:1104–1110. doi: 10.1056/NEJMoa030505. [DOI] [PubMed] [Google Scholar]
  • 89.Salvatore CA, Hersey JC, Corcoran HA, et al. Pharmacological characterization of MK-0974 [N-[(3R,6S)-6-(2,3-difluorophenyl)-2-oxo-l-(2,2,2-trifluoroethyl)azepan-3-yl]-4-(2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl) piperidine-1-carboxamide], a potent and orally active calcitonin gene-related peptide receptor antagonist for the treatment of migraine. J Pharmacol Exp Ther. 2008;324:416–421. doi: 10.1124/jpet.107.130344. [DOI] [PubMed] [Google Scholar]
  • 90.Chan KY, Edvinsson L, Eftekhari S, et al. Characterization of the CGRP receptor antagonist telcagepant in human isolated cerebral and meningeal arteries. Cephalalgia. 2009;29(Suppl 1):131–131. [Google Scholar]
  • 91.Sinclair S, et al. The novel oral CGRP antagonist, MK-0974, exhibits similar pharmacokinetics during and between migraine attacks. Cephalalgia. 2007;27(Suppl 1):738–738. [Google Scholar]
  • 92.Han TH, Blanchard RL, Palcza J, et al. Single- and multiple-dose pharmacokinetics and tolerability of telcagepant, an oral calcitonin gene-related peptide receptor antagonist, in adults. J Clin Pharmacol 2010 Feb 19 [Epub ahead of print]. [DOI] [PubMed]
  • 93.de Hoon J, et al. Lack of significant pharmacodynamic interaction between telcagepant 600 mg and sumatriptan 100 mg. Cephalalgia. 2009;29:1349–1349. [Google Scholar]
  • 94.Ho TW, Mannix LK, Fan X, MK-0974 Protocol 004 Study Group et al. Randomized controlled trial of an oral CGRP receptor antagonist, MK-0974, in acute treatment of migraine. Neurology. 2008;70:1304–1312. doi: 10.1212/01.WNL.0000286940.29755.61. [DOI] [PubMed] [Google Scholar]
  • 95.Ho TW, Ferrari MD, Dodick DW, et al. Efficacy and tolerability of MK-0974 (telcagepant), a new oral antagonist of calcitonin gene-related peptide receptor, compared with zolmitriptan for acute migraine: a randomised, placebo-controlled, parallel-treatment trial. Lancet. 2008;372:2115–2123. doi: 10.1016/S0140-6736(08)61626-8. [DOI] [PubMed] [Google Scholar]
  • 96.Ho AP, Dahlof CGH, Silberstein SD, et al. Randomized, controlled, trial of telcagepant over four migraine attacks. Cephalalgia 2010 (in press). [DOI] [PubMed]
  • 97.Ho T, Connor K, Dahlof C, et al. Assessment of the long term safety and tolerability of telcagepant for the intermittent treatment of acute migraine: a double-blind, active-controlled study. Cephalalgia. 2009;29(Suppl 1):12–12. [Google Scholar]
  • 98.Connor KM, Shapiro RE, Diener HC, et al. Randomized, controlled trial of telcagepant for the acute treatment of migraine. Neurology. 2009;73:970–977. doi: 10.1212/WNL.0b013e3181b87942. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 99.Sur C, Hargreaves R, Bell I, et al. CSF levels and binding pattern of novel CGRP receptor antagonists in rhesus monkey and human central nervous system: toward the development of a PET tracer. Cephalalgia. 2009;29(Suppl 1):136–137. [Google Scholar]
  • 100.Storer RJ, Akerman S, Goadsby PJ. Calcitonin gene-related peptide (CGRP) modulates nociceptive trigeminovascular transmission in the cat. Br J Pharmacol. 2004;142:1171–1181. doi: 10.1038/sj.bjp.0705807. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 101.Fischer MJ, Koulchitsky S, Messlinger K. The nonpeptide calcitonin gene-related peptide receptor antagonist BIBN4096BS lowers the activity of neurons with meningeal input in the rat spinal trigeminal nucleus. J Neurosci. 2005;25:5877–5883. doi: 10.1523/JNEUROSCI.0869-05.2005. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 102.Di Angelantonio S, Giniatullin R, Costa V, Sokolova E, Nistri A. Modulation of neuronal nicotinic receptor function by the neuropeptides CGRP and substance P on autonomic nerve cells. Br J Pharmacol. 2003;139:1061–1073. doi: 10.1038/sj.bjp.0705337. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 103.Yu Y, Lundeberg T, Yu LC. Role of calcitonin gene-related peptide and its antagonist on the evoked discharge frequency of wide dynamic range neurons in the dorsal hom of the spinal cord in rats. Regul Pept. 2002;103:23–27. doi: 10.1016/S0167-0115(01)00326-3. [DOI] [PubMed] [Google Scholar]
  • 104.Giniatullin R, Nistri A, Fabbretti E. Molecular Mechanisms of sensitization of pain-transducing P2X3 receptors by the migraine mediators CGRP and NGF. Mol Neurobiol. 2008;37:83–90. doi: 10.1007/s12035-008-8020-5. [DOI] [PubMed] [Google Scholar]
  • 105.Sun RQ, Lawand NB, Willis WD. The role of calcitonin gene-related peptide (CGRP) in the generation and maintenance of mechanical allodynia and hyperalgesia in rats after intradermal injection of capsaicin. Pain. 2003;104:201–208. doi: 10.1016/S0304-3959(03)00008-3. [DOI] [PubMed] [Google Scholar]
  • 106.Liu Y, Broman J, Edvinsson L. Central projections of the sensory innervation of the rat middle meningeal artery. Brain Res. 2008;1208:103–110. doi: 10.1016/j.brainres.2008.02.078. [DOI] [PubMed] [Google Scholar]
  • 107.Morara S, Wang LP, Filippov V, et al. Calcitonin gene-related peptide (CGRP) triggers Ca2+ responses in cultured astrocytes and in Bergmann glial cells from cerebellar slices. Eur J Neurosci. 2008;28:2213–2220. doi: 10.1111/j.1460-9568.2008.06514.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 108.Morara S, van der Want JJ, de Weerd H, Provini L, Rosina A. Ultrastructural analysis of climbing fiber-Purkinje cell synaptogenesis in the rat cerebellum. Neuroscience. 2001;108:655–671. doi: 10.1016/S0306-4522(01)00433-X. [DOI] [PubMed] [Google Scholar]
  • 109.Morara S, Rosina A, Provini L, Forloni G, Caretti A, Wimalawansa SJ. Calcitonin gene-related peptide receptor expression in the neurons and glia of developing rat cerebellum: an autoradiographic and immunohistochemical analysis. Neuroscience. 2000;100:381–391. doi: 10.1016/S0306-4522(00)00276-1. [DOI] [PubMed] [Google Scholar]
  • 110.Sándor PS, Mascia A, Scidel L, de Pasqua V, Schoenen J. Sub-clinical cerebellar impairment in the common types of migraine: a three-dimensional analysis of reaching movements. Ann Neurol. 2001;49:668–672. doi: 10.1002/ana.1019. [DOI] [PubMed] [Google Scholar]
  • 111.Brighina F, Palermo A, Panetta ML, et al. Reduced cerebellar inhibition in migraine with aura: a TMS study. Cerebellum. 2009;8:260–266. doi: 10.1007/s12311-008-0090-4. [DOI] [PubMed] [Google Scholar]
  • 112.Pecile A, Guidobono F, Netti C, Sibilia V, Biella G, Braga PC. Calcitonin gene-related peptide: antinociceptive activity in rats, comparison with calcitonin. Regul Pept. 1987;18:189–199. doi: 10.1016/0167-0115(87)90007-3. [DOI] [PubMed] [Google Scholar]
  • 113.Huang Y, Brodda-Jansen G, Lundeberg T, Yu LC. Anti-nociceptive effects of calcitonin gene-related peptide in nucleus raphe magnus of rats: an effect attenuated by naloxone. Brain Res. 2000;873:54–59. doi: 10.1016/S0006-8993(00)02473-2. [DOI] [PubMed] [Google Scholar]
  • 114.Ferrari MD, Goadsby PJ, Roon KI, Lipton RB. Triptans (serotonin, 5-HT1B/1D agonists) in migraine: detailed results and methods of a meta-analysis of 53 trials [Erratum in: Cephalalgia 2003; 23:71] Cephalalgia. 2002;22:633–658. doi: 10.1046/j.1468-2982.2002.00404.x. [DOI] [PubMed] [Google Scholar]

Articles from Neurotherapeutics are provided here courtesy of Elsevier

RESOURCES